Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Enzymatica AB: BioStock: Final study results - ColdZyme reduces illness duration and alleviates symptoms

Enzymatica

An independent investigator-initiated study from the University of Kent demonstrates that Enzymatica's mouth spray ColdZyme reduces the duration of upper respiratory tract infections by up to five days in endurance athletes, enabling faster return to training. Additionally, ColdZyme alleviates symptoms and decreases the viral load of rhinovirus, the most common cause of a cold. Principal investigator Glen Davison shared insights on these results in an interview with BioStock.

Read the full article at biostock.se (https://www.biostock.se/en/):

https://www.biostock.se/en/2024/09/final-study-results-coldzyme-reduces-illness-duration-and-alleviates-symptoms/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team